Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis

Objectives 5-aminosalicylate (mesalazine; 5-ASA) is an established first-line treatment for mild-to-moderate ulcerative colitis (UC). This study aimed to model the benefits of optimising 5-ASA therapy.Methods A decision tree model followed 10 000 newly diagnosed patients with mild-to-moderately acti...

Full description

Saved in:
Bibliographic Details
Main Authors: Fernando Magro, Jakob Begun, Edouard Louis, Simon PL Travis, Alexander R Moschen, Neeraj Narula, Grazyna Rydzewska, Jae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, Axel U Dignass, Juan Ricardo Márquez, Matthew J Freddi
Format: Article
Language:English
Published: BMJ Publishing Group 2022-10-01
Series:BMJ Open Gastroenterology
Online Access:https://bmjopengastro.bmj.com/content/9/1/e000853.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopengastro.bmj.com/content/9/1/e000853.full

Similar Items